Results 31 to 40 of about 2,906,691 (234)

The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma

, 2021
Pseudomyxoma Peritonei (PMP) and Peritoneal Mesothelioma (PM) are both rare peritoneal malignancies. Currently, affected patients may be treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy offering long-term survival or even ...
de Hingh, I.,, Deraco, M.,, Glehen, O.,, Govaerts, K.,, Kepenekian, V.,, Kusamura, S.,, Lund University., Lurvink, R.J,, Moran, B.,, PSOGI, Syk, Ingvar,, Van der Speeten, K.,, Villeneuve, L.,   +12 more
core   +1 more source

Cytoreductive surgery in ovarian cancer [PDF]

Cancer Imaging, 2007
As the overall prognosis for patients with ovarian cancer is poor, the management of this condition should be restricted to expert multi-disciplinary teams in gynaecological oncology. Apparent early stage ovarian cancer requires accurate and complete staging so that potential sites for metastases are not missed.
Pomel, Christophe, Jeyarajah, Arjun, Oram, David, Shepherd, John, Milliken, David, Dauplat, Jacques, Reynolds, Karina   +6 more
openaire   +2 more sources

An Unusual Cause of Abdominal Ascites. [PDF]

, 2018
Abdominal ascites is most commonly caused by portal hypertension from liver cirrhosis. When present, portal hypertension is associated with an elevated serum-ascites albumin gradient (SAAG) ≥1.1 g/dL. In contrast, a SAAG < 1.1 g/dL suggests malignancy,
Chak, Eric W, Olson, Kristin A, Wong, Kimberly A   +2 more
core   +2 more sources

Cost-effectiveness of primary debulking surgery when compared to neoadjuvant chemotherapy in the management of stage IIIC and IV epithelial ovarian cancer. [PDF]

, 2016
ObjectivesTo examine the cost-effectiveness of primary debulking surgery (PDS) when compared to neoadjuvant chemotherapy (NACT) in the management of epithelial ovarian cancer (EOC) using Surveillance, Epidemiology, and End Results data linked to Medicare
Chang, Jenny, Forde, Gareth K, Ziogas, Argyrios   +2 more
core   +1 more source

Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial

International Journal of Gynecological Cancer, 2020
Background The addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery improves recurrence-free and overall survival in patients with FIGO stage III ovarian cancer who are ineligible for primary cytoreductive ...
S. Koole, R. V. van Stein, K. Sikorska, D. Barton, L. Perrin, D. Brennan, O. Zivanovic, B. Mosgaard, A. Fagotti, Pierre-Emmanuel Colombo, G. Sonke, W. J. V. Driel   +11 more
semanticscholar   +1 more source

Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer

JAMA Network Open, 2020
Key Points Question Is the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to primary cytoreductive surgery (PCS) associated with better outcomes for patients with stage III epithelial ovarian cancer?
Z. Lei, Yue Wang, Jiahong Wang, Ke Wang, Jun Tian, Ying Zhao, Lipai Chen, Jin Wang, Jiali Luo, M. Jia, Hong-sheng Tang, Qingjun He, Quanxing Liao, Xiansheng Yang, T. Guan, Li Wang, S. Cui   +16 more
semanticscholar   +1 more source

Evidence for engraftment of human bone marrow cells in non-lethally irradiated baboons [PDF]

, 1997
Background. Prior to organ harvesting, an attempt was made to modulate the donor's immune responses against prospective xenogeneic recipients by infusion of 'recipient-type' bone marrow. Methods.
Fontes, P, Fung, JJ, Rao, AS, Ricordi, C, Rogers, J, Starzl, TE, Trucco, M, Zeevi, A   +7 more
core   +1 more source

Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis.

Journal of Clinical Oncology, 2019
PURPOSE Gastric cancer (GC) with peritoneal metastases (PMs) is a poor prognostic evolution. Cytoreductive surgery (CRS) yields promising results, but the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) remains controversial. Here we aimed to
P. Bonnot, G. Piessen, V. Képénékian, E. Decullier, M. Pocard, B. Meunier, J. Bereder, K. Abboud, F. Marchal, F. Quénet, D. Goéré, S. Msika, C. Arvieux, N. Pirró, R. Wernert, P. Rat, J. Gagnière, J. Lefèvre, T. Courvoisier, R. Kianmanesh, D. Vaudoyer, M. Rivoire, P. Meeus, G. Passot, O. Glehen   +24 more
semanticscholar   +1 more source

Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a clinical practice guideline.

Current Oncology, 2020
Objective The purpose of the present review was to provide evidence-based guidance about the provision of cytoreductive surgery (crs) with hyperthermic intraperitoneal chemotherapy (hipec) in the treatment of peritoneal cancers.
R. Auer, D. Sivajohanathan, J. Biagi, J. Conner, E. Kennedy, T. May   +5 more
semanticscholar   +1 more source

The Peritoneal Cancer Index is a Strong Predictor of Incomplete Cytoreductive Surgery in Ovarian Cancer

Annals of Surgical Oncology, 2020
Background Extent of tumor load is an important factor in the selection of ovarian cancer patients for cytoreductive surgery (CRS). The Peritoneal Cancer Index (PCI) gives exact information on tumor load but still is not standard in ovarian cancer ...
B. Jónsdóttir, M. Lomnytska, I. Poromaa, I. Silins, K. Stålberg   +4 more
semanticscholar   +1 more source